UPDATE 1-Glaxo Saudi's sole supplier of H1N1 vaccine for now

* Saudi Arabia to start H1N1 inoculation with pilgrims

* Glaxo is kingdom's sole supplier of H1N1 vaccine for now

RIYADH, Nov 7 (Reuters) - British drugmaker GlaxoSmithKline (GSK.L) is currently Saudi Arabia's sole supplier of an H1N1 flu vaccine but the kingdom may include other firms for the supply of a nationwide inoculation campaign, the health ministry said.

Saudi Arabia's vaccination campaign was launched on Saturday and will first focus on pilgrims and health workers.

"For the moment, the only vaccine that has been authorised is the GlaxoSmithKline vaccine Pandemrix," health ministry spokesman Khaled Mirghalani told Reuters.

"We will in the future get vaccines from other clients, from other companies, as soon as they get approved by the SFDA (Saudi Food and Drug Authority)," he said.

Around 3 million Muslim pilgrims from more than 160 countries take part in the haj in the holy city of Mecca most years, including up to 2 million who travel from abroad. Haj this year will start in during the last week of November.

Disease experts from the United States and Arab countries, including Saudi Arabia, have said waves of the H1N1 flu virus spread by pilgrims travelling to and from Mecca for haj could put pressure on healthcare systems around the world.